0.4883
price up icon5.62%   0.026
after-market Handel nachbörslich: .49 0.0017 +0.35%
loading
Schlusskurs vom Vortag:
$0.4623
Offen:
$0.488
24-Stunden-Volumen:
419.23K
Relative Volume:
0.16
Marktkapitalisierung:
$20.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-74.56M
KGV:
-0.2666
EPS:
-1.8316
Netto-Cashflow:
$-60.27M
1W Leistung:
+17.95%
1M Leistung:
+59.31%
6M Leistung:
-44.02%
1J Leistung:
-63.01%
1-Tages-Spanne:
Value
$0.4526
$0.505
1-Wochen-Bereich:
Value
$0.4056
$0.505
52-Wochen-Spanne:
Value
$0.2201
$1.54

Rallybio Corp Stock (RLYB) Company Profile

Name
Firmenname
Rallybio Corp
Name
Telefon
203- 859-3820
Name
Adresse
234 CHURCH STREET, NEW HAVEN
Name
Mitarbeiter
24
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
RLYB's Discussions on Twitter

Vergleichen Sie RLYB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RLYB
Rallybio Corp
0.4883 17.23M 0 -74.56M -60.27M -1.8316
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Rallybio Corp Stock (RLYB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-09 Herabstufung H.C. Wainwright Buy → Neutral
2024-05-15 Herabstufung JP Morgan Overweight → Neutral
2024-02-07 Herabstufung Jefferies Buy → Hold
2023-04-17 Eingeleitet H.C. Wainwright Buy
2023-04-10 Eingeleitet Wedbush Outperform
2022-12-09 Eingeleitet JP Morgan Overweight
2022-02-22 Eingeleitet JMP Securities Mkt Outperform
2021-08-23 Eingeleitet Cowen Outperform
2021-08-23 Eingeleitet Evercore ISI Outperform
2021-08-23 Eingeleitet Jefferies Buy
Alle ansehen

Rallybio Corp Aktie (RLYB) Neueste Nachrichten

pulisher
Jul 22, 2025

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Rallybio Corporation Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Rallybio Corporation stockHigh-octane gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

What drives Rallybio Corporation stock priceUnmatched market gains - printweek.in

Jul 20, 2025
pulisher
Jul 19, 2025

Is Rallybio Corporation a good long term investmentTremendous gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN

Jul 17, 2025
pulisher
Jul 16, 2025

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Rallybio Corporation stock attracts strong analyst attentionFree Join Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - MSN

Jul 13, 2025
pulisher
Jul 11, 2025

Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN

Jul 11, 2025
pulisher
Jul 10, 2025

We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st

Jul 10, 2025
pulisher
Jul 09, 2025

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz

Jul 08, 2025
pulisher
Jul 08, 2025

RallyBio - Hartford Business Journal

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal

Jul 08, 2025
pulisher
Jul 08, 2025

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech

Jul 08, 2025
pulisher
Jul 08, 2025

Recursion Pharmaceuticals Acquires Full Interest in Joint Hypophosphatasia Candidate From Rallybio - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio sells interest in REV102 program to Recursion Pharmaceuticals - grafa.com

Jul 08, 2025
pulisher
Jul 08, 2025

Rallybio Sells REV102 Program to Recursion Pharmaceuticals - TipRanks

Jul 08, 2025
pulisher
Jul 07, 2025

ImmunoPrecise Strengthens Board with 30-Year Biotech Veteran Jon Lieber from Rallybio - Stock Titan

Jul 07, 2025

Finanzdaten der Rallybio Corp-Aktie (RLYB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):